Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Diclofenac/misoprostol during early pregnancy and the risk of miscarriage: a Danish nationwide cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The increasing role of a retained placenta in postpartum blood loss: a cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Letter to the editor

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  3. Failed manual removal of the placenta after vaginal delivery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Ponderal index at birth associates with later risk of gestational diabetes mellitus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Anal incontinence after two vaginal deliveries without obstetric anal sphincter rupture

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. How patients in Denmark acquire their medicines: overview, data sources and implications for pharmacoepidemiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Adaptive COVID-19 Treatment Trial-1 (ACTT-1) in a real-world population: a comparative observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Differential time responses in inflammatory and oxidative stress markers after a marathon: An observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Misoprostol can be used in the prevention of gastric ulcer in treatment with diclofenac and is used in rheumatic diseases. Since misoprostol causes contractions of the uterus, it can also be used to induce abortions when administrated vaginally. The aim of the study was to investigate if early pregnancy exposure to oral diclofenac/misoprostol was associated with miscarriage.

METHOD: We conducted a nationwide cohort study identifying all registered pregnancies in Denmark from 1997 to 2011. All births were identified using the Medical Birth Registry, and all records of induced abortion and miscarriage were from the National Hospital Register. Data on drug use were from the National Prescription Register. Cox proportional hazard regression models were used to calculate the hazard of miscarriage in women exposed to diclofenac/misoprostol in early pregnancy.

RESULT: We identified 1,338,824 pregnancies (970,491 births, 142,147 miscarriages, 226,145 induced abortions). One hundred sixty-six were exposed to diclofenac/misoprostol in the early pregnancy of which 28.3 % (47) ended up in a miscarriage compared to 10.6 % among unexposed. The adjusted hazard ratio of having a miscarriage after exposure to diclofenac/misoprostol in the first trimester was 3.6 (CI 95 % 2.6-4.9).

CONCLUSION: We found an increased risk of miscarriage after exposure to diclofenac/misoprostol during the early pregnancy. Women in the fertile age should not be treated with the combination of diclofenac/misoprostol if other options were available.

OriginalsprogEngelsk
TidsskriftArchives of Gynecology and Obstetrics
ISSN0932-0067
DOI
StatusUdgivet - 19 nov. 2015

ID: 45833242